- NCI's Frederick National Laboratory for Cancer Research operations and technical support contractor Leidos Biomedical Research awards the molecular testing contract for ALCHEMIST to Response Genetics (OTC:RGDX +3.8%). The contract will run 5 - 6 years and will involve screening thousands of early-stage lung cancer patients for EGFR gene mutations and ALK gene rearrangement.
- ALCHEMIST consists of three integrated studies (one screening and two treatment) implemented through the National Clinical Trials Network of the National Cancer Institute.
- The specific monetary size is not disclosed, but is referred to as "multimillion."